Near-Infrared Spectroscopy Combined with Absorbance Upper Optimization Partial Least Squares Applied to Rapid Analysis of Polysaccharide for Proprietary Chinese Medicine Oral Solution

Near-infrared (NIR) spectroscopy was applied to reagent-free quantitative analysis of polysaccharide of a brand product of proprietary Chinese medicine (PCM) oral solution samples. A novel method, called absorbance upper optimization partial least squares (AUO-PLS), was proposed and successfully applied to the wavelength selection. Based on varied partitioning of the calibration and prediction sample sets, the parameter optimization was performed to achieve stability. On the basis of the AUO-PLS method, the selected upper bound of appropriate absorbance was 1.53 and the corresponding wavebands combination was 400 - 1880 & 2088 - 2346 nm. With the use of random validation samples excluded from the modeling process, the root-mean-square error and correlation coefficient of prediction for polysaccharide were 27.09 mg·L-1 and 0.888, respectively. The results indicate that the NIR prediction values are close to those of the measured values. NIR spectroscopy combined with AUO-PLS method provided a promising tool for quantification of the polysaccharide for PCM oral solution and this technique is rapid and simple when compared with conventional methods.

Development of MIP Technology and Its Proprietary Catalysts

A novel catalytic cracking process named the MIP process was developed by the Research Institute of Petroleum Processing(RIPP),SINOPEC,to manufacture clean gasoline with lower olefin contents. The MIP pro-cess features a unique riser consisting of two sequential reaction zones with different radii,in which different kinds of chemical reactions are intensified respectively to achieve better product slates and product properties. In order to fully implement the MIP potentials,a proprietary catalyst RMI tailored to the needs of the MIP process was devel-oped by adopting an AIRY zeolite having improved accessibility to active sites,which could result in better heavy oil cracking,coke selectivity and olefin reduction performance compared with the conventional REUSY zeolite. Its commercial application showed that the RMI catalyst could further reduce the olefin content in gasoline and raise the gasoline octane number while increasing the total liquid yield. On the basis of the MIP process,the MIP-CGP process was also developed to significantly reduce the olefin content in FCC naphtha and to enhance the propylene yield simultaneously. As far as the MIP-CGP process itself is concerned,both the MIP-CGP process and the MIP process have the similar reactor configuration but with different reactor size and operating parameters. The proprietary catalyst CGP-1 is also proposed to tailor for the MIP-CGP process. The specific features of the CGP-1 catalyst cover the new matrix,which possesses excellent capability to accommodate coke formation in the first reaction zone;the modified Y zeolite,which exhibits high hydrogen transfer activity in the second reaction zone;and the MFI zeolite,which has good gasoline olefin cracking activity. The commercial test results of MIP-CGP process applied along with the CGP-1 catalyst showed that the olefin content of gasoline was less than 18 v% and the propylene yield was more than 8 m%. Furthermore,as compared with the conventional FCC process,the gasoline properties were improved greatly and a higher total liquid yield was obtained. The advantages and characteristics of the MIP-CGP process were fully exploited by using the CGP-1 catalyst.

Tolerability of a Proprietary Larch Arabinogalactan Extract: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Healthy Subjects

In a placebo-controlled, double-blind, randomized clinical trial, the tolerability of a proprietary larch arabinogalactan preparation (ResistAidTM) was investigated. METHODS: 199 healthy participants were randomly assigned to receive either placebo (n = 98) or an arabinogalactan preparation (n = 101) over a period of 12 weeks. As safety parameters the total number of adverse events, changes in various biochemical and laboratory parameters as well as the global evaluation of tolerability by investigator and subjects compared to placebo were evaluated. RESULTS: In total 16 adverse events were observed in 16 subjects, with no difference between the arabinogalactan and the placebo group (p = 0.935). There were no differences in the mean changes of the measured biochemical and laboratory parameters. The tolerability of the arabinogalactan extract was rated as “very good” or “good” by the investigators for 99% of the subjects and by 98% subjects in self-assessment with no statistical differences to placebo. CONCLUSION: The measured parameters as well as the evaluation of the tolerability by the investigators and the subjects demonstrate a very good tolerance profile of the proprietary arabinogalactan extract with no differences to placebo when taken for 12 weeks.

Strengthening Protection Of Proprietary Intellectual Property Rights and Implementation of Technology Standard Strategies

This article focuses on the current situation in technical research and development （R＆D） and proprietary intellectual property rights （IPRs） in China. Based on the situation of Far East Cable Company, it analyzes the significance of strengthening the protection of proprietary IPRs and implementing a strategy for technology standards and then discusses the actual work and future arrangement of proprietary IPRs and technology standard strategies. It points out that the enhancement of proprietary IPRs protection and implementation of technology standard strategies is the only way for enterprises to remain competitive.

Evolution of the registration regulations for proprietary Chinese medicines in China

In this review, we provide a comprehensive overview on the registration of proprietary Chinese medicines(PCMs) in China over the past century by examining published literature and historical data. We will examine this evolving administrative practice for PCMs registration in China, which is divided to the following five stages:(1) initial measures(1915-1948);(2) early development(1949-1965);(3) provincial approval and trial implementation of the "approval number" system(1966-1984);(4) legislation and cleanup(1985-1999); and(5) centralized national approval(2000 until now), offering a panoramic view on the characteristics of PCMs registration management in China.

Integrating traditional Chinese (herbal) medicines into risk based regulation-With focus on non-clinical requirements to demonstrate safety

Within the public health sector of Hong Kong(China),there is a consensus around the important role of traditional Chinese medicines.For Hong Kong(China)to play a bridging role to bring Chinese medicines to the global market requires a concerted effort from the government,academic institutes and industries.The release of the final version of the European Medicines Agencies guidance document,which details the acceptance of minimum requirements to nonclinical package in bibliographical applications,grants the opportunity for well-established and traditional herbal medicines to demonstrate an‘acceptable safe’status for registration in the European Union.It is anticipated that this minimum nonclinical package can be applied to demonstrate the safe use of many traditional Chinese medicines regardless of their eligibility to be registered under the simplified procedure within the European Union.This paper conceptualizes an integration of a simplified evaluation route for eligible proprietary Chinese medicines(pCm)with long history of use into the existing drug regulatory framework in Hong Kong(China).Such integration utilizing the minimum nonclinical package,based on bibliographical data or expert report,as proof of evidence to demonstrate safety for pCm with long history of use requires less demand in scientific resources.With Hong Kong(China)conducting‘first hand’review for eligible pCm,it provides an option for overseas and local pharmaceutical companies to register their products in Hong Kong(China)without the need to rely on issuance of Certificate of Pharmaceutical Product from other countries.This could bring eligible pCm with long history of use to reach international risk-based standard and to be marketed globally as‘medicines’to reach their full therapeutic potential.An important process to positioning Hong Kong(China)to compete with other countries in promoting importation and exportation of pCm to better serve the global health.

Institutional Changes and Globalisation Alter the Landscape of Chinese Auto Industry

In light of the institutional environment transformation and globalisation, this article draws on institutional theory and global value chain theory to explore the growth path of China's state-owned automakers. The study finds that the institution and globalisation factors have become the growth driver of state-owned automakers. At each stage, it is found that there is a convergence in the organisational behaviour of state-owned automakers. The change in driving force, has, however, led to the transformation of organisational behaviour of those state-owned automobile enterprises undergoing the process of evolving from a joint venture model to a proprietary innovation model. This change has come about due to the leveraging of partnership opportunities with multinational motor companies.

Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease:Important role of lipid metabolism

Metabolic dysfunction-associated steatotic liver disease(MASLD),formerly known as non-alcoholic fatty liver disease,has a high global prevalence and can progress to metabolic dysfunction-associated steatohepatitis,cirrhosis,and hepatocellular carcinoma.The pathogenesis of MASLD is primarily driven by disturbances in hepatic lipid metabolism,involving six key processes:increased hepatic fatty acid uptake,enhanced fatty acid synthesis,reduced oxidative degradation of fatty acids,increased cholesterol uptake,elevated cholesterol synthesis,and increased bile acid synthesis.Consequently,maintaining hepatic lipid metabolic homeostasis is essential for effective MASLD management.Numerous novel molecules and Chinese proprietary medicines have demonstrated promising therapeutic potential in treating MASLD,primarily by inhibiting lipid synthesis and promoting lipid oxidation.In this review,we summarized recent research on MASLD,elucidated the molecular mechanisms by which lipid metabolism disorders contribute to MASLD pathogenesis,and discussed various lipid metabolism-targeted therapeutic approaches for MASLD.

Mandatory information disclosure and innovation:Evidence from the disclosure of operational information

We use a quasi-natural experiment wherein the Shanghai Stock Exchange requires listed companies in certain industries to disclose operational information and a staggered difference-in-differences model to examine the impact of mandatory information disclosure on corporate innovation.We find that companies subject to mandatory operational information disclosure show significantly increased innovation.This effect is pronounced for companies classified as non-state-owned enterprises,facing severe financing constraints and a high degree of shareholder tunneling behavior and in competitive and high-tech industries.Although mandatory operational information disclosure reduces their competitive advantage,companies appear to compensate by increasing innovation.Our study highlights the positive impact of mandatory operational information disclosure,indicating that it contributes to the highquality development of both capital markets and companies.

中国社会办医现状及对策

鼓励和引导社会资本发展医疗卫生事业，形成投资主体多元化、投资方式多样化的办医体制，是深化医药卫生体制改革确定的基本原则和重要内容。社会办医疗机构是我国医疗卫生服务体系不可或缺的重要组成部分。2009年4月中共中央国务院颁布《关于深化医药卫生体制改革的意见》（中发（2009]6号），

香港私营医疗系统概述

香港医疗服务体系的特点是公营和私营医疗市场并行。这两个市场涵盖从基础护理到专科医疗、门诊服务到大型手术护理，甚至涉及公众教育、疾病预防及复康管理等。公营体系主要由医院管理局提供门诊及医院服务，当中依靠以地区为分域的急症、普通科、专科门诊及住院服务等，收费极低，相当于政府提供的免费医疗。

Brief Introduction of TianHe Exascale Prototype System

Facing the challenges of the next generation exascale computing,National University of Defense Technology has developed a prototype system to explore opportunities,solutions,and limits toward the next generation Tianhe system.This paper briefly introduces the prototype system,which is deployed at the National Supercomputer Center in Tianjin and has a theoretical peak performance of 3.15 Pflops.A total of 512 compute nodes are found where each node has three proprietary CPUs called Matrix-2000+.The system memory is 98.3 TB,and the storage is 1.4 PB in total.

Gene deletor： a new tool to address gene flow and food safety concerns over transgenic crop plants

Environmental and food safety concerns over transgenic plants have hampered commercial applications of transgenic plant technology worldwide. A recently developed transgene deletion technology, named gene deletor technology, may be used to eliminate all transgenes from pollen, seeds, fruits or other organs when functions of transgenes are no longer needed or their presence may cause concerns. In this review, I will briefly describe the principle of the gene deletor technology with major supporting experimental data. I will also explain main characteristics and requirements of the gene deletor technology. Finally, I will discuss the gene deletor technology in the context of how it may be used to alleviate environmental and food safety concerns over transgenic plants in vegetatively and sexually propagated plants, to prevent volunteer transgenic plants, to protect proprietary transgenic technologies, and to allow farmers to reuse their harvested seeds for future planting.

台湾私人医疗体系

1台湾医疗体系简介台湾的医疗行政机构分成中央和地方，中央最高的等级是行政院卫生署（DOH），其管理、指导及监督全国的医疗行政事务，并与地方的卫生局合作。